Terumo Corp. (4543) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.85 M

Shareholding (Mar 2025)

FII

0.02%

Held by 4 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Low Debt Company with Strong Long Term Fundamental Strength

Healthy long term growth as Net Sales has grown by an annual rate of 10.50%
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 36.60
The company has been able to generate a Return on Capital Employed (avg) of 11.11% signifying high profitability per unit of total capital (equity and debt)

Positive results in Jun 25

With ROE of 8.55%, it has a attractive valuation with a 2.81 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 3,916,821 Million (Large Cap)

P/E

33.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

9.13%

Price to Book

2.86

Revenue and Profits:

Net Sales:

259,965 Million

(Quarterly Results - Jun 2025)

Net Profit:

41,843 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.27%

6 Months

-13.02%

1 Year

-24.06%

2 Years

-2.67%

3 Years

-42.16%

4 Years

-50.88%

5 Years

-44.06%

Terumo Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Terumo Corp. Stock Hits Day Low Amid Price Pressure, Closes at JPY 2,442.00

Terumo Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a decline in stock price today, reflecting ongoing market challenges. Despite recent fluctuations, the company shows strong long-term fundamentals, including a healthy EBIT to Interest ratio and consistent net sales growth, while underperforming against the Japan Nikkei 225.

Terumo Corp. Hits Day Low of JPY 2,473 Amid Price Pressure

Terumo Corp. faced a decline in its stock price, reflecting ongoing market challenges. Despite a modest monthly gain, the company has experienced significant year-to-date and long-term declines. However, it maintains strong fundamentals, including a healthy EBIT to Interest ratio and robust net sales growth, though its return on equity suggests a premium valuation.

Terumo Corp. Stock Hits Day High with Strong 5.3% Intraday Surge

Terumo Corp. has seen a rise in stock performance, reaching an intraday high and showing a weekly increase that slightly outpaces the Japan Nikkei 225. Despite a year-to-date decline and long-term underperformance, the company maintains a solid financial foundation with consistent net sales growth and a strong market capitalization.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.50%

EBIT Growth (5y)

10.47%

EBIT to Interest (avg)

36.60

Debt to EBITDA (avg)

0.20

Net Debt to Equity (avg)

-0.03

Sales to Capital Employed (avg)

0.62

Tax Ratio

24.25%

Dividend Payout Ratio

32.91%

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

11.10%

ROE (avg)

8.48%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.81

EV to EBIT

21.22

EV to EBITDA

14.37

EV to Capital Employed

2.88

EV to Sales

3.67

PEG Ratio

Dividend Yield

ROCE (Latest)

13.55%

ROE (Latest)

8.55%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 4 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -1.50% vs 0.15% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 127.95% vs -48.17% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "259,965.00",
          "val2": "263,936.00",
          "chgp": "-1.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "74,669.00",
          "val2": "59,430.00",
          "chgp": "25.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,278.00",
          "val2": "2,423.00",
          "chgp": "-47.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "41,843.00",
          "val2": "18,356.00",
          "chgp": "127.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "205.70%",
          "val2": "143.80%",
          "chgp": "6.19%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 12.40% vs 12.39% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 9.97% vs 19.09% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,036,171.00",
          "val2": "921,863.00",
          "chgp": "12.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "264,471.00",
          "val2": "210,941.00",
          "chgp": "25.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2,016.00",
          "val2": "2,065.00",
          "chgp": "-2.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24,728.00",
          "val2": "-2,008.00",
          "chgp": "-1,131.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "116,978.00",
          "val2": "106,374.00",
          "chgp": "9.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "172.80%",
          "val2": "145.60%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

259,965.00

263,936.00

-1.50%

Operating Profit (PBDIT) excl Other Income

74,669.00

59,430.00

25.64%

Interest

1,278.00

2,423.00

-47.26%

Exceptional Items

0.00

Consolidate Net Profit

41,843.00

18,356.00

127.95%

Operating Profit Margin (Excl OI)

205.70%

143.80%

6.19%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -1.50% vs 0.15% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 127.95% vs -48.17% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,036,171.00

921,863.00

12.40%

Operating Profit (PBDIT) excl Other Income

264,471.00

210,941.00

25.38%

Interest

2,016.00

2,065.00

-2.37%

Exceptional Items

-24,728.00

-2,008.00

-1,131.47%

Consolidate Net Profit

116,978.00

106,374.00

9.97%

Operating Profit Margin (Excl OI)

172.80%

145.60%

2.72%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 12.40% vs 12.39% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 9.97% vs 19.09% in Mar 2024

All Annual Results

Company CV

About Terumo Corp.

Terumo Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Terumo Corp.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Low Debt Company with Strong Long Term Fundamental Strength

Positive results in Jun 25

With ROE of 8.55%, it has a attractive valuation with a 2.81 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Terumo Corp. Stock Hits Day Low Amid Price Pressure, Closes at JPY 2,442.00

Terumo Corp. Hits Day Low of JPY 2,473 Amid Price Pressure

Terumo Corp. Stock Hits Day High with Strong 5.3% Intraday Surge

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Mar'25

About Terumo Corp.

Company Coordinates